Wall Street Turns Bullish on Capricor as FDA Extends Review for Deramiocel to November
Oppenheimer raises Capricor to Outperform on clearer path for deramiocel. $54 target, PDUFA Nov 22 after upper-limb focus.
/ 1648 items
#XY↓
Wolfe Research Upgrades Moderna to Peer Perform After Cancer Vaccine Breakthrough
Wolfe Research upgrades Moderna to Peer Perform following Phase 3 intismeran success and a potential $9.2 billion peak sales outlook.
Guardant Health Ordered to Pay Over $245 Million in DNA Sequencing Patent Dispute
Court orders Guardant Health to pay over $245.2M for willfully infringing TwinStrand’s DNA sequencing patents. Ongoing 6% royalties apply; Guardant will appeal.
Alvotech: BofA Initiates Buy Rating as Biosimilar Launch Cycle Begins
FDA clears Reykjavik plant as biosimilar launches drive commercial growth.
Visa Flags Hims & Hers Over Excessive Disputes on $149 Weight-Loss Subscriptions
Visa flags Hims for high dispute rates on $39-to-$149 weight-loss memberships. Company faces fees, scrutiny, and must lower rate for 3 months.
Capricor Gets Three Extra Months as FDA Reviews Stronger Upper-Limb Data for Deramiocel
FDA extends Capricor’s Deramiocel BLA review to Nov 22, 2026 after new 24-month HOPE-3 data focused on upper limb function in Duchenne MD.